28. Systemic amyloidosis Clinical trials / Disease details

Clinical trials : 267 /  Drugs : 241 - (DrugBank : 77) / Drug target genes : 68 - Drug target pathways : 180

  
2 trials found
No.TrialIDDate_
enrollment		Date_
registration		Public_titleScientific_titleConditionInterventionPrimary_
sponsor		Secondary_
sponsor		Recruitment_
Status		Inclusion_
agemin		Inclusion_
agemax		Inclusion_
gender		Target_
size		PhaseCountries
1NCT05692908
(ClinicalTrials.gov)		March 202311/1/2023An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL AmyloidosisAn Open-Label, Dose-Escalation Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL AmyloidosisLight Chain (AL) AmyloidosisBiological: STI-6129Sorrento Therapeutics, Inc.NULLNot yet recruiting18 YearsN/AAll36Phase 1NULL
2NCT04316442
(ClinicalTrials.gov)		April 1, 202116/3/2020Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL AmyloidosisA Phase 1b/2a, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With Relapsed or Refractory Systemic AL AmyloidosisLight Chain (AL) AmyloidosisBiological: STI-6129Sorrento Therapeutics, Inc.NULLRecruiting18 YearsN/AAll60Phase 1/Phase 2United States